Abstract
In summary, our study reveals a relatively high expression of complement regulatory proteins on the surface of plasma cells, which appears to be a constitutive feature of these cells, rather than a specific change induced by a malignant state. Further efforts will aim at establishing a correlation between CD55 and CD59 expression levels and in vitro and in vivo resistance to rituximab.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 919-921 |
| Number of pages | 3 |
| Journal | Leukemia and Lymphoma |
| Volume | 47 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2006 |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'High expression of CD59 and CD55 on benign and malignant plasma cells'. Together they form a unique fingerprint.
Cite this
Alcindor, T., Kimlinger, T., & Witzig, T. E. (2006). High expression of CD59 and CD55 on benign and malignant plasma cells. Leukemia and Lymphoma, 47(5), 919-921. https://doi.org/10.1080/10428190500467784